Quick Answer
Alaunos Therapeutics, Inc. reported Total Assets of $2.97 million for the year ending 2025.
- Alaunos Therapeutics, Inc. showed an increase of +7.7% in Total Assets from 2024 to 2025.
- This data is from Alaunos Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2009: $49.74 million | Q3 2010: $67.45 million | Q3 2011: $122.28 million | Q1 2012: $140.87 million | Q3 2012: $105.64 million | Q1 2013: $63.35 million | Q2 2013: $45.60 million | Q3 2013: $29.48 million | Q1 2014: $63.33 million | Q2 2014: $55.35 million | Q3 2014: $49.11 million | Q1 2015: $131.65 million | Q2 2015: $124.04 million | Q3 2015: $173.36 million | Q1 2016: $141.68 million | Q2 2016: $128.01 million | Q3 2016: $117.12 million | Q1 2017: $94.49 million | Q2 2017: $126.81 million | Q3 2017: $116.56 million | Q1 2018: $87.46 million | Q2 2018: $76.38 million | Q3 2018: $66.80 million | Q1 2019: $83.50 million | Q2 2019: $73.17 million | Q3 2019: $117.95 million | Q1 2020: $198.28 million | Q2 2020: $181.68 million | Q3 2020: $165.89 million | Q1 2021: $128.47 million | Q2 2021: $106.77 million | Q3 2021: $113.76 million | Q1 2022: $84.99 million | Q2 2022: $73.93 million | Q3 2022: $67.34 million | Q1 2023: $48.64 million | Q2 2023: $27.93 million | Q3 2023: $19.44 million | Q1 2024: $6.04 million | Q2 2024: $4.68 million | Q3 2024: $3.55 million | Q1 2025: $2.12 million | Q2 2025: $4.74 million | Q3 2025: $3.72 million.
- Over the full 16 years of available data (2010 to 2025), Alaunos Therapeutics, Inc.'s Total Assets has declined by 95.2%.
- Historical annual values: Fiscal year 2025: $2.97 million | Fiscal year 2024: $2.76 million | Fiscal year 2023: $8.26 million | Fiscal year 2022: $64.94 million | Fiscal year 2021: $94.87 million | Fiscal year 2020: $146.35 million | Fiscal year 2019: $109.11 million | Fiscal year 2018: $95.05 million | Fiscal year 2017: $105.61 million | Fiscal year 2016: $106.35 million | Fiscal year 2015: $153.72 million | Fiscal year 2014: $45.24 million | Fiscal year 2013: $71.75 million | Fiscal year 2012: $83.40 million | Fiscal year 2011: $108.11 million | Fiscal year 2010: $61.52 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: